Morningstar has reiterated a ‘Buy’ rating for AstraZeneca (NASDAQ: AZN) with a fair value estimate of $78 per share, which represents a potential upside from the current market price of $65.19.
Market expert Ashish Chaturvedi has suggested four BUY Calls and no SELL Call for today’s trading session, indicating a bullish outlook for Indian markets.
Pharmaceutical major Wockhardt has signed a deal with the UK government to supply COVID-19 vaccine under development and testing by AstraZeneca and researchers from Oxford University.
